Human Insulin Analogs: Evaluation of Inflammatory mRNA Expression of Macrophages and Endothelial Function of Short-acting Insulin - HERMES Pilot Study

Inclusion Criteria: * Type 2 diabetes mellitus * Stable BOT (basal oral therapy) with Insulin Glargine + ≥ 2 OHA (oral hypoglycemic agents except for TZD) for a minimum of three months before entering the study * HbA1c ≤ 8.5% * Age between 30 and 75 years inclusively * Body mass index ≤ 40 kg/m2 * Patient consents that his/her family physician will be informed of trial participation Exclusion Criteria: * Type 1 diabetes mellitus * Unspecific infection or inflammation (hsCRP \>10mg/L in POC test) * Use of thiazolidinediones within the last 3 months prior to study start * Retinopathy, hepatic or renal dysfunction or clinically relevant other major diseases * History of drug or alcohol abuse within the last five years prior to screening * History of hypersensitivity to the study drugs (or any component of the study drug) or to drugs with similar chemical structures * History of severe or multiple allergies * Treatment with any other investigational drug within 3 months prior to screening * Progressive fatal disease * hepatic (ALAT and/or ASAT \> 3 times the normal reference range), renal (creatinine \> 1.3 mg/dl in women and \> 1.6 mg/dl in men), neurological, psychiatric and/or hematological disease as judged by the investigator * Pregnant or lactating women * Sexually active women of childbearing potential not consistently and correctly practicing birth control by implants, injectables, combined oral contraceptives, hormonal intrauterine devices (IUDs), sexual abstinence or vasectomized partner * Lack of compliance or other similar reason that, according to investigator, precludes satisfactory participation in the study